Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?

Key Takeaways How the Decision Affects NVO's Competitive Edge in Obesity Novo Nordisk had signed the partnership agreement with HIMS in late April. Through the deal, the company was also trying to grow its obesity market share by boosting sales through increased patient access to Wegovy. NVO faces intense competition from Eli Lilly (LLY) , which markets its tirzepatide medicines, Mounjaro (diabetes) and Zepbound (obesity). Despite being on the market for less than three years, Lilly's Mounjaro and Zepbound ...